Patent · US Active

6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine

US9796718B2 · kind B2 · utility

14Cited by

20References

2Claims

0Family size

Assignee

GILEAD CONNECTICUT, INC. · US

Inventors

Scott A. Mitchell · East Haven, US
Kevin S. Currie · North Branford, US
Peter A. Blomgren · Issaquah, US
Jeffrey E. Kropf · Branford, US
Seung H. Lee · Sammamish, US
Jianjun Xu · Bellevue, US
Douglas G. Stafford · Niskayuna, US
James P. Harding · Loudonville, US
Antonio J.M. BARBOSA · Middlebury, US
Zhongdong Zhao · Guilford, US
David M. Armistead · Maynard, US
Soumya Mitra · Liverpool, US

Key dates

Filing date	Oct 13, 2015
Grant date	Oct 24, 2017
Priority date	—
Expiry date	Oct 13, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/91205
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are imidazopyrazine compounds, particularly including 6-(benzo[d]thiazol-5-yl)-N-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine, structure below, and methods and formulations for their use in inhibiting Spleen Tyrosine Kinase in treating conditions including B-cell lymphomas or leukemias and inflammatory conditions:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.